{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:30:45Z","timestamp":1791509445170,"version":"4.3.4"},"reference-count":288,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson\u2019s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.<\/jats:p>","DOI":"10.3390\/toxins13010042","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T23:03:42Z","timestamp":1610319822000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Botulinum Toxin in Movement Disorders: An Update"],"prefix":"10.3390","volume":"13","author":[{"given":"Charenya","family":"Anandan","sequence":"first","affiliation":[{"name":"Parkinson\u2019s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"ref_1","unstructured":"Padda, I.S., and Tadi, P. (2020). Botulinum Toxin. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rossetto, O., Pirazzini, M., Fabris, F., and Montecucco, C. (2020). Botulinum Neurotoxins: Mechanism of Action. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/164_2020_355"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lonati, D., Schicchi, A., Crevani, M., Buscaglia, E., Scaravaggi, G., Maida, F., Cirronis, M., Petrolini, V.M., and Locatelli, C.A. (2020). Foodborne botulism: Clinical diagnosis and medical treatment. Toxins, 12.","DOI":"10.3390\/toxins12080509"},{"key":"ref_5","first-page":"18","article-title":"Detection and Quantification of Biologically Active Botulinum Neurotoxin Serotypes A and B Using a F\u00f6rster Resonance Energy Transfer-Based Quantum Dot Nanobiosensor","volume":"9","author":"Wang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212586","article-title":"Use of botulinum toxin for movement disorders","volume":"8","author":"Camargo","year":"2019","journal-title":"Drugs Context"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: Genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-1331.2010.03056.x","article-title":"On muscle spindles, dystonia and botulinum toxin","volume":"17","author":"Rosales","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: State of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type a poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"Meunier","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1113\/jphysiol.2008.153569","article-title":"Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A","volume":"586","author":"Rogozhin","year":"2008","journal-title":"J. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum a toxin for cranial-cervicaldystonia: A double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","volume":"147","author":"Jankovic","year":"2018","journal-title":"Toxicon"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mdc3.12613","article-title":"Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study","volume":"5","author":"Jankovic","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.22336\/rjo.2018.24","article-title":"Injecting botulinum toxin into the treatment of blepharospasm","volume":"61","author":"Popescu","year":"2018","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dressler, D. (2019). Clinical Pharmacology of Botulinum Toxin Drugs. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/164_2019_273"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1212\/01.wnl.0000327865.05877.17","article-title":"Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A","volume":"71","author":"Atassi","year":"2008","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity associated with botulinum toxin treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Andraweera, N.D., Andraweera, P.H., Lassi, Z.S., and Kochiyil, V. (2020). Effectiveness of Botulinum Toxin A injection in managing mobility related outcomes in adult patients with cerebral palsy\u2014Systematic review. Am. J. Phys. Med. Rehabil.","DOI":"10.1097\/PHM.0000000000001653"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0039-1694988","article-title":"Botulinum Toxin in Children with Cerebral Palsy: An Update","volume":"51","author":"Hareb","year":"2020","journal-title":"Neuropediatrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104682","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104682","article-title":"Botulinum Toxin Type A for Upper Limb Spasticity in Poststroke Patients: A Meta-analysis of Randomized Controlled Trials","volume":"29","author":"Jia","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: A consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Balint, B., Mencacci, N.E., Valente, E.M., Pisani, A., Rothwell, J., Jankovic, J., Vidailhet, M., and Bhatia, K.P. (2018). Dystonia. Nat. Rev. Dis. Prim., 4.","DOI":"10.1038\/s41572-018-0023-6"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/joor.12768","article-title":"Oromandibular dystonia, mental distress and oro-facial dysfunction\u2014A follow-up 8\u201310 years after start of treatment with botulinum toxin","volume":"46","author":"Bakke","year":"2019","journal-title":"J. Oral Rehabil."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/mds.25244","article-title":"The prevalence of primary dystonia: A systematic review and meta-analysis","volume":"27","author":"Steeves","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13548506.2018.1549740","article-title":"Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm","volume":"24","author":"Tang","year":"2019","journal-title":"Psychol. Health Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0002-9394(85)90228-4","article-title":"Treatment of blepharospasm with botulinum toxin","volume":"99","author":"Tsoy","year":"1985","journal-title":"Am. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-017-3107-2","article-title":"A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: Preseptal and pretarsal botulinum toxin injection techniques","volume":"38","author":"Lolekha","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_35","first-page":"45","article-title":"Blepharospasm: Update on epidemiology, clinical aspects, and pathophysiology","volume":"7","author":"Defazio","year":"2016","journal-title":"Front. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00002826-198610000-00002","article-title":"Botulinum injection therapy for blepharospasm: A review and report of 75 patients","volume":"9","author":"Cohen","year":"1986","journal-title":"Clin. Neuropharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archopht.1984.01040031184014","article-title":"Treatment of Blepharospasm with Botulinum Toxin: A Preliminary Report","volume":"102","author":"Frueh","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0161-6420(87)33338-X","article-title":"Effectiveness of Botulinum Toxin Therapy for Essential Blepharospasm","volume":"94","author":"Engstrom","year":"1987","journal-title":"Ophthalmology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/bjo.71.9.664","article-title":"Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections","volume":"71","author":"Elston","year":"1987","journal-title":"Br. J. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1017\/S0317167100026159","article-title":"Botulinum Toxin for Benign Essential Blepharospasm, Hemifacial Spasm and Age-Related Lower Eyelid Entropion","volume":"14","author":"Carruthers","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1136\/bmj.290.6485.1857","article-title":"Effect of treatment with botulinum toxin on neurogenic blepharospasm","volume":"290","author":"Elston","year":"1985","journal-title":"Br. Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.35.10.1499","article-title":"Blepharospasm, meige syndrome, and hemifacial spasm: Treatment with botulinunn toxin","volume":"35","author":"Mauriello","year":"1985","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0161-6420(88)32977-5","article-title":"Long-term Results and Complications of Botulinum A Toxin in the Treatment of Blepharospasm","volume":"95","author":"Dutton","year":"1988","journal-title":"Ophthalmology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1212\/WNL.43.4.834","article-title":"Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia","volume":"43","author":"Jankovic","year":"1993","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/112067210301300401","article-title":"Treatment of blepharospasm with botulinum neurotoxin type A: Long-term results","volume":"13","author":"Calace","year":"2003","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp.59.3.309","article-title":"Pretarsal application of botulinum toxin for treatment of blepharospasm","volume":"59","author":"Aramideh","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/jnnp.60.6.693-a","article-title":"Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients","volume":"60","author":"Albanese","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Costa, J., Ferreira, J.J., Coelho, M.M., Borges, A.A., Esp\u00edrito-Santo, C.C., Moore, P., Sampaio, C., Borges, A.A., Ferreira, J.J., and Coelho, M.M. (2004). Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004900"},{"key":"ref_50","first-page":"CD004900","article-title":"Botulinum toxin type A therapy for blepharospasm","volume":"11","author":"Duarte","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_51","first-page":"1","article-title":"Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: Study protocol for a randomised controlled trial","volume":"17","author":"Wickwar","year":"2016","journal-title":"Trials"},{"key":"ref_52","first-page":"625","article-title":"Comparison of two different formulations of botulinum toxin a for the treatment of blepharospasm and hemifacial spasm","volume":"21","author":"Wu","year":"2011","journal-title":"Turk. Neurosurg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/WNF.0b013e3181c46f61","article-title":"Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0161-6420(97)30220-6","article-title":"Blepharospasm and hemifacial spasm: Randomized trial to determine the most appropriate location for botulinum toxin injections","volume":"104","author":"Price","year":"1997","journal-title":"Ophthalmology"},{"key":"ref_55","first-page":"178","article-title":"Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm","volume":"27","author":"Li","year":"2012","journal-title":"Eye Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/ene.12009","article-title":"Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy","volume":"20","author":"Lungu","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IOP.0b013e31819946c4","article-title":"High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference?","volume":"25","author":"Boyle","year":"2009","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport\u00ae) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Park. Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Jost","year":"2006","journal-title":"J. Neural Transm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1531-8257(199911)14:6<1017::AID-MDS1018>3.0.CO;2-3","article-title":"Combined use of type A and F botulinum toxins for blepharospasm: A double-blind controlled trial","volume":"14","author":"Mezaki","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","year":"1997","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_63","first-page":"583","article-title":"Blepharospasm and oromandibular-laryngeal-cervical dystonia: A controlled trial of botulinum a toxin therapy","volume":"50","author":"Jankovic","year":"1988","journal-title":"Adv. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1007\/s12325-020-01427-6","article-title":"IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Na\u00efve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"37","author":"Mitsikostas","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3341\/kjo.2016.0123","article-title":"Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study","volume":"33","author":"Sane","year":"2019","journal-title":"Korean J. Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.toxicon.2018.02.006","article-title":"Systematic review of botulinum toxin treatment for oromandibular dystonia","volume":"147","author":"Comella","year":"2018","journal-title":"Toxicon"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1044\/2017_AJSLP-16-0098","article-title":"Self-rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections","volume":"26","author":"Page","year":"2017","journal-title":"Am. J. Speech-Lang. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14802\/jmd.17065","article-title":"Oromandibular Dystonia: Demographics and Clinical Data from 240 Patients","volume":"11","author":"Slaim","year":"2018","journal-title":"J. Mov. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.parkreldis.2015.08.022","article-title":"Hyoid muscle dystonia: A distinct focal dystonia syndrome","volume":"21","author":"Norby","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","article-title":"Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up","volume":"53","author":"Tan","year":"1999","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/lary.23265","article-title":"Oromandibular dystonia: Long-term management with botulinum toxin","volume":"123","author":"Sinclair","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jocn.2014.08.027","article-title":"Successful treatment of open jaw and jaw deviation dystonia with botulinum toxin using a simple intraoral approach","volume":"22","author":"Moscovich","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00702-018-1960-7","article-title":"Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: A meta-analysis","volume":"126","author":"Dadgardoust","year":"2019","journal-title":"J. Neural Transm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.11607\/ofph.1955","article-title":"Computer-Aided Design\/Computer-Assisted Manufacture-Derived Needle Guide for Injection of Botulinum Toxin into the Lateral Pterygoid Muscle in Patients with Oromandibular Dystonia","volume":"32","author":"Yoshida","year":"2018","journal-title":"J. Oral Facial Pain Headache"},{"key":"ref_75","first-page":"291","article-title":"Bruxism in craniocervical dystonia: A prospective study","volume":"34","author":"Borie","year":"2016","journal-title":"Cranio-J. Craniomandib. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jopr.12479","article-title":"Bruxism in Movement Disorders: A Comprehensive Review","volume":"26","author":"Ella","year":"2017","journal-title":"J. Prosthodont."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/jnnp.53.6.530","article-title":"Treatment of bruxism with botulinum toxin injections","volume":"53","author":"Marchau","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0003-9993(97)90343-9","article-title":"Bruxism after brain injury: Successful treatment with botulinum toxin-A","volume":"78","author":"Ivanhoe","year":"1997","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14219\/jada.archive.2000.0149","article-title":"Treating severe bruxism with botulinum toxin","volume":"131","author":"Tan","year":"2000","journal-title":"J. Am. Dent. Assoc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/joor.12914","article-title":"The effect of botulinum toxin injections on bruxism: A systematic review","volume":"47","author":"Sahin","year":"2020","journal-title":"J. Oral Rehabil."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sendra, L.A., Montez, C., Vianna, K.C., and Barboza, E.P. (2020). Clinical outcomes of botulinum toxin type a injections in the management of primary bruxism in adults: A systematic review. J. Prosthet. Dent.","DOI":"10.1016\/j.prosdent.2020.06.002"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1212\/WNL.0000000000004951","article-title":"Onabotulinum toxin-A injections for sleep bruxism","volume":"90","author":"Ondo","year":"2018","journal-title":"Neurology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4103\/ijdr.IJDR_125_17","article-title":"Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism","volume":"28","author":"Jadhao","year":"2017","journal-title":"Indian J. Dent. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5664\/jcsm.3532","article-title":"Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: A polysomnographic evaluation","volume":"10","author":"Shim","year":"2014","journal-title":"J. Clin. Sleep Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PHM.0b013e3181bc0c78","article-title":"Effect of botulinum toxin injection on nocturnal bruxism: A randomized controlled trial","volume":"89","author":"Lee","year":"2010","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00415-016-8185-1","article-title":"Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue","volume":"263","author":"Nastasi","year":"2016","journal-title":"J. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yoshida, K. (2019). Botulinum neurotoxin therapy for lingual dystonia using an individualized injection method based on clinical features. Toxins, 11.","DOI":"10.3390\/toxins11010051"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.parkreldis.2010.04.007","article-title":"Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy","volume":"16","author":"Esper","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2007.09.010","article-title":"Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature","volume":"32","author":"Hennings","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/mds.26920","article-title":"Phenotype- and genotype-specific structural alterations in spasmodic dysphonia","volume":"32","author":"Bianchi","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/lary.25273","article-title":"Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients","volume":"125","author":"Blitzer","year":"2015","journal-title":"Laryngoscope"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamaoto.2018.0644","article-title":"Consensus-based attributes for identifying patients with spasmodic dysphonia and other voice disorders","volume":"144","author":"Ludlow","year":"2018","journal-title":"JAMA Otolaryngol.-Head Neck Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ene.13731","article-title":"Spread of dystonia in patients with idiopathic adult-onset laryngeal dystonia","volume":"25","author":"Esposito","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Berman, B.D., Groth, C.L., Sillau, S.H., Pirio Richardson, S., Norris, S.A., Junker, J., Br\u00fcggemann, N., Agarwal, P., Barbano, R.L., and Espay, A.J. (2019). Risk of spread in adult-onset isolated focal dystonia: A prospective international cohort study. J. Neurol. Neurosurg. Psychiatry, 91.","DOI":"10.1136\/jnnp-2019-321794"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/lary.20564","article-title":"Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia","volume":"119","author":"Vasconcelos","year":"2009","journal-title":"Laryngoscope"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0269215506cr931oa","article-title":"Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): A systematic Cochrane review","volume":"20","author":"Watts","year":"2006","journal-title":"Clin. Rehabil."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/mus.23409","article-title":"Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia","volume":"46","author":"Hong","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.parkreldis.2012.04.005","article-title":"Muscle selection for treatment of cervical dystonia with botulinum toxin\u2014A systematic review","volume":"18","author":"Nijmeijer","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00415-019-09527-2","article-title":"How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study","volume":"266","author":"Colosimo","year":"2019","journal-title":"J. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2019.02.020","article-title":"Remission in dystonia\u2014Systematic review of the literature and meta-analysis","volume":"66","author":"Mainka","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-019-02116-7","article-title":"Frequency of different subtypes of cervical dystonia: A prospective multicenter study according to Col\u2013Cap concept","volume":"127","author":"Jost","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Farrell, M., Karp, B.I., Kassavetis, P., Berrigan, W., Yonter, S., Ehrlich, D., and Alter, K.E. (2020). Management of anterocapitis and anterocollis: A novel ultrasound guided approach combined with electromyography for botulinum toxin injection of longus colli and longus capitis. Toxins, 12.","DOI":"10.3390\/toxins12100626"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: A critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency","volume":"246","author":"Kessler","year":"1999","journal-title":"J. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","article-title":"A long-term follow-up of botulinum toxin a in cervical dystonia","volume":"31","author":"Mohammadi","year":"2009","journal-title":"Neurol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20-year follow-up","volume":"90","author":"Jankovic","year":"2014","journal-title":"Toxicon"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Castel\u00e3o, M., Marques, R.E., Duarte, G.S., Rodrigues, F.B., Ferreira, J., Sampaio, C., Moore, A.P., and Costa, J. (2017). Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev., 2017.","DOI":"10.1002\/14651858.CD003633.pub3"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Costa, J., Esp\u00edrito-Santo, C.C., Borges, A.A., Ferreira, J., Coelho, M.M., Moore, P., and Sampaio, C. (2004). Botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004315.pub2"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Costa, J., Esp\u00edrito-Santo, C.C., Borges, A.A., Ferreira, J., Coelho, M.M., Moore, P., and Sampaio, C. (2005). Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD003633.pub2"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Costa, J., Esp\u00edrito-Santo, C.C., Borges, A.A., Moore, P., Ferreira, J., Coelho, M.M., and Sampaio, C. (2005). Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004312.pub2"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.6061\/clinics\/2019\/e776","article-title":"Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia","volume":"74","author":"Vilanova","year":"2019","journal-title":"Clinics"},{"key":"ref_112","first-page":"105","article-title":"Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia","volume":"29","author":"Kaymak","year":"2018","journal-title":"Phys. Med. Rehabil."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Marques, R.E., Duarte, G.S., Rodrigues, F.B., Castel\u00e3o, M., Ferreira, J., Sampaio, C., Moore, A.P., and Costa, J. (2016). Botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004315.pub3"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Duarte, G.S., Castel\u00e3o, M., Rodrigues, F.B., Marques, R.E., Ferreira, J., Sampaio, C., Moore, A.P., and Costa, J. (2016). Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004314.pub3"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: Comparing onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","article-title":"Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia","volume":"67","author":"Jankovic","year":"2006","journal-title":"Neurology"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Delnooz, C.C.S., Pasman, J.W., Beckmann, C.F., and van de Warrenburg, B.P.C. (2013). Task-Free Functional MRI in Cervical Dystonia Reveals Multi-Network Changes That Partially Normalize with Botulinum Toxin. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062877"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.nicl.2019.101792","article-title":"Cause or effect: Altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment","volume":"22","author":"Brodoehl","year":"2019","journal-title":"Neuroimage Clin."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00221-018-5322-3","article-title":"Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: A functional MRI study","volume":"236","author":"Hok","year":"2018","journal-title":"Exp. Brain Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5334\/tohm.348","article-title":"The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography","volume":"7","author":"Mahajan","year":"2017","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2014.10.013","article-title":"Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia","volume":"73","author":"Delnooz","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00207454.2011.623807","article-title":"Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: An fMRI Study","volume":"122","author":"Otruba","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-016-8136-x","article-title":"Botulinum toxin treatment failures in cervical dystonia: Causes, management, and outcomes","volume":"263","author":"Jinnah","year":"2016","journal-title":"J. Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Comella, C., Ferreira, J.J., Pain, E., Azoulai, M., and Om, S. (2020). Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J. Neurol., 1\u201310.","DOI":"10.1007\/s00415-020-10217-7"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2014.09.034","article-title":"Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia","volume":"21","author":"Ferreira","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00415-010-5880-1","article-title":"Evolution of dose and response to botulinum toxin A in cervical dystonia: A multicenter study","volume":"258","author":"Burguera","year":"2011","journal-title":"J. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10072-009-0097-8","article-title":"Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia","volume":"30","author":"Felicio","year":"2009","journal-title":"Neurol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/mds.20670","article-title":"Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia","volume":"20","author":"Skogseid","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","article-title":"Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: A retrospective analysis","volume":"121","author":"Hefter","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.parkreldis.2019.02.035","article-title":"A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia","volume":"63","author":"Hu","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Yi, Y.G., Kim, K., Yi, Y., Choi, Y.A., Leigh, J.H., and Bang, M.S. (2018). Botulinum toxin type a injection for cervical dystonia in adults with dyskinetic cerebral palsy. Toxins, 10.","DOI":"10.3390\/toxins10050203"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00415-018-8819-6","article-title":"Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance","volume":"265","author":"Samotus","year":"2018","journal-title":"J. Neurol."},{"key":"ref_134","first-page":"1989","article-title":"Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia","volume":"19","author":"Huang","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNF.0b013e3181c46f48","article-title":"A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia","volume":"33","author":"Quagliato","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-na\u00efve patients with cervical dystonia: Randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/mds.21145","article-title":"Botulinum toxin and neuromotor rehabilitation: An integrated appraoch to idiopathic cervical dystonia","volume":"21","author":"Tassorelli","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical Dystonia: Results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000057902","article-title":"Low-dose botulinum toxin-A treatment of cervical dystonia\u2014A double-blind, randomized pilot study","volume":"47","author":"Fries","year":"2002","journal-title":"Eur. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","article-title":"A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia","volume":"249","author":"Naumann","year":"2002","journal-title":"J. Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","article-title":"Efficacy and safety of a standardised 500 unit dose of Dysport\u00ae (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled","volume":"248","author":"Wissel","year":"2001","journal-title":"J. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/apmr.2001.21843","article-title":"Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: A comparative study between a home and a clinic treatment service","volume":"82","author":"Whitaker","year":"2001","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.51.3.815","article-title":"Electromyography in cervical dystonia: Changes after botulinum and trihexyphenidyl","volume":"51","author":"Brans","year":"1998","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport\u00ae","volume":"64","author":"Poewe","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type b: A double-blind, placebo controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0168-5597(94)90150-3","article-title":"Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study","volume":"93","author":"Werdelin","year":"1994","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mds.26085","article-title":"Dysport and botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study","volume":"30","author":"Yun","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/09638280701568742","article-title":"Restoring balance in focal limb dystonia with botulinum toxin","volume":"29","author":"Sheean","year":"2007","journal-title":"Disabil. Rehabil."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0166-2236(90)90007-W","article-title":"Writer\u2019s cramp","volume":"13","author":"Marsden","year":"1990","journal-title":"Trends Neurosci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mds.870060110","article-title":"Writer\u2019s cramp: Treatment with botulinum toxin injections","volume":"6","author":"Rivest","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxicon.2019.07.010","article-title":"Botulinum toxin and occupational therapy for Writer\u2019s cramp","volume":"169","author":"Park","year":"2019","journal-title":"Toxicon"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Gupta, A.D., Tucker, G., Koblar, S., Visvanathan, R., and Cameron, I.D. (2018). Spatiotemporal gait analysis and lower limb functioning in foot dystonia treated with botulinum toxin. Toxins, 10.","DOI":"10.3390\/toxins10120532"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2007.08.024","article-title":"Focal hand dystonia, mirror dystonia and motor overflow","volume":"266","author":"Sitburana","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/mds.21446","article-title":"Community survey of primary dystonia in the city of Kolkata, India","volume":"22","author":"Das","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","article-title":"Botulinum toxin for writer\u2019s cramp: A randomised, placebo-controlled trial and 1-year follow-up","volume":"78","author":"Kruisdijk","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","article-title":"Botulinum toxin in the treatment of writer\u2019s cramp: A double-blind study","volume":"43","author":"Tsui","year":"1993","journal-title":"Neurology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1212\/01.WNL.0000149768.36634.92","article-title":"Botulinum toxin injections in the treatment of musician\u2019s dystonia","volume":"64","author":"Schuele","year":"2005","journal-title":"Neurology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/brb3.1182","article-title":"Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome","volume":"9","author":"Unti","year":"2019","journal-title":"Brain Behav."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/mds.23504","article-title":"Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more","volume":"26","author":"Lungu","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1109\/TOH.2016.2601605","article-title":"Haptic Feedback Manipulation during Botulinum Toxin Injection Therapy for Focal Hand Dystonia Patients: A Possible New Assistive Strategy","volume":"9","author":"Atashzar","year":"2016","journal-title":"IEEE Trans. Haptics"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","article-title":"Double-Blind trial of botulinum toxin for treatment of focal hand dystonia","volume":"10","author":"Cole","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2020.08.035","article-title":"Self-reported benefit and weakness after botulinum toxin in dystonia","volume":"80","author":"Kassavetis","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2340\/16501977-2094","article-title":"Botulinum toxin for foot dystonia in patients with Parkinson\u2019s disease having deep brain stimulation: A Case series and a pilot study","volume":"48","author":"Gupta","year":"2016","journal-title":"J. Rehabil. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870100317","article-title":"\u201cOff\u201d painful dystonia in Parkinson\u2019s disease treated with botulinum toxin","volume":"10","author":"Pacchetti","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_172","first-page":"526","article-title":"Effect of botulinum toxin A & task-specific training on upper limb function in post-stroke focal dystonia","volume":"68","author":"Umar","year":"2018","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100038506","article-title":"Localizing muscles for botulinum toxin treatment of focal hand dystonia","volume":"23","author":"Geenen","year":"1996","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00702-010-0416-5","article-title":"Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy","volume":"117","author":"Szczudlik","year":"2010","journal-title":"J. Neural Transm."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IIO.0000000000000203","article-title":"Botulinum toxins for treating essential blepharospasm and hemifacial spasm","volume":"58","author":"Ozzello","year":"2018","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000266389.52843.3b","article-title":"The other Babinski sign in hemifacial spasm","volume":"69","author":"Stamey","year":"2007","journal-title":"Neurology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-012-0987-z","article-title":"Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: A nerve conduction study","volume":"34","author":"Butera","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0036-1571952","article-title":"Botulinum Toxin Treatment of Blepharospasm, Orofacial\/Oromandibular Dystonia, and Hemifacial Spasm","volume":"36","author":"Karp","year":"2016","journal-title":"Semin. Neurol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1179\/174313209X431129","article-title":"Treatment with botulinum toxin improves the hyperexcitability of the facial motoneuron in patients with hemifacial spasm","volume":"32","author":"Ishikawa","year":"2010","journal-title":"Neurol. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archopht.1985.01050090057031","article-title":"Hemifacial Spasm Treated With Botulinum A Toxin Injection","volume":"103","author":"Savino","year":"1985","journal-title":"Arch. Ophthalmol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","article-title":"Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm","volume":"53","author":"Jankovic","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_182","first-page":"133","article-title":"Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: A Canadian multicentre study","volume":"26","author":"Taylor","year":"1991","journal-title":"Can. J. Ophthalmol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1590\/0004-282x20160191","article-title":"Treatment of hemifacial spasm with botulinum toxin type a: Effective, long lasting and well tolerated","volume":"75","author":"Batisti","year":"2017","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1442-9071.1994.tb00793.x","article-title":"Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm","volume":"22","author":"Price","year":"1994","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9394(03)00075-8","article-title":"Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm","volume":"136","author":"Snir","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","article-title":"Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: A multicentre study using two drug-dose escalation indexes","volume":"24","author":"Cillino","year":"2010","journal-title":"Eye"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1442-9071.2010.02303.x","article-title":"Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm","volume":"38","author":"Cannon","year":"2010","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3126\/kumj.v8i3.6217","article-title":"The role of the injection botulinum toxin A in cases of essential blepharospasm syndrome, hemifacial spasm and meige\u2019s syndrome","volume":"8","author":"Bastola","year":"2010","journal-title":"Kathmandu Univ. Med. J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/jnnp.74.5.687","article-title":"Botulinum toxin type B in blepharospasm and hemifacial spasm","volume":"74","author":"Colosimo","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/PL00007849","article-title":"Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm","volume":"249","author":"Ozturk","year":"2002","journal-title":"J. Neurol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/mds.27789","article-title":"Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm","volume":"34","author":"Sacramento","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Duarte, G.S., Rodrigues, F.B., Castel\u00e3o, M., Marques, R.E., Ferreira, J., Sampaio, C., Moore, A.P., and Costa, J. (2020). Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst. Rev., 11.","DOI":"10.1002\/14651858.CD004899.pub3"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Costa, J., Esp\u00edrito-Santo, C.C., Borges, A.A., Ferreira, J., Coelho, M.M., Moore, P., and Sampaio, C. (2005). Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004899.pub2"},{"key":"ref_194","first-page":"335","article-title":"Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm","volume":"21","author":"Kalra","year":"1990","journal-title":"Ophthalmic Surg."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm","volume":"2","author":"Brin","year":"1987","journal-title":"Mov. Disord."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jocn.2007.02.002","article-title":"Differences in improvement between patients with idiopathic versus neurovascular hemifacial spasm after botulinum toxin treatment","volume":"15","author":"Okuyucu","year":"2008","journal-title":"J. Clin. Neurosci."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Lu, A.Y., Yeung, J.T., Gerrard, J.L., Michaelides, E.M., Sekula, R.F., and Bulsara, K.R. (2014). Hemifacial spasm and neurovascular compression. Sci. World J., 2014.","DOI":"10.1155\/2014\/349319"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00415-018-8960-2","article-title":"Botulinum toxin therapy of hemifacial spasm: Bilateral injections can reduce facial asymmetry","volume":"265","author":"Xiao","year":"2018","journal-title":"J. Neurol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4238\/2015.February.6.17","article-title":"Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: A randomized double-blind crossover trial","volume":"14","author":"Li","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_200","first-page":"1119","article-title":"The difference of treatment results between botulinum toxin a split injection sites and botulinum toxin a non-split injection sites for hemifacial spasm","volume":"98","author":"Prutthipongsit","year":"2015","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_201","first-page":"48","article-title":"Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study","volume":"95","author":"Kongsengdao","year":"2012","journal-title":"J. Med. Assoc. Thai."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000327534","article-title":"Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm? A randomized, single-blind, crossover trial","volume":"65","author":"Colakoglu","year":"2011","journal-title":"Eur. Neurol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/mus.880150909","article-title":"Treatment of hemifacial spasm with botulinum toxin","volume":"15","author":"Yoshimura","year":"1992","journal-title":"Muscle Nerve"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.parkreldis.2019.01.023","article-title":"Botulinum toxin for the treatment of tremor","volume":"63","author":"Mittal","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_205","first-page":"1","article-title":"Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor","volume":"9","author":"Kreisler","year":"2019","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Samotus, O., Lee, J., and Jog, M. (2019). Personalized bilateral upper limb essential tremor therapy with botulinum toxin using kinematics. Toxins, 11.","DOI":"10.3390\/toxins11020125"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","article-title":"Botulinum toxin treatment of tremors","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mds.870090604","article-title":"Botulinum toxin a injections for the treatment of hand tremors","volume":"9","author":"Trosch","year":"1994","journal-title":"Mov. Disord."},{"key":"ref_209","first-page":"1","article-title":"Effective management of upper limb parkinsonian tremor by incobotulinumtoxina injections using sensor-based biomechanical patterns","volume":"2015","author":"Rahimi","year":"2015","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/cjn.2017.260","article-title":"Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics","volume":"45","author":"Samotus","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Niemann, N., and Jankovic, J. (2018). Botulinum toxin for the treatment of hand tremor. Toxins, 10.","DOI":"10.3390\/toxins10070299"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","article-title":"A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor","volume":"11","author":"Jankovic","year":"1996","journal-title":"Mov. Disord."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","article-title":"A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor","volume":"56","author":"Brin","year":"2001","journal-title":"Neurology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/mds.25739","article-title":"Treatment of proximal upper limb tremor with botulinum toxin therapy","volume":"29","author":"Kim","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s100720070049","article-title":"Botulinum toxin treatment for functional disability induced by essential tremor","volume":"21","author":"Pacchetti","year":"2000","journal-title":"Neurol. Sci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.parkreldis.2018.06.019","article-title":"Botulinum toxin in essential hand tremor\u2014A randomized double-blind placebo-controlled study with customized injection approach","volume":"56","author":"Mittal","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.mayocp.2017.06.010","article-title":"Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study with a Customized Injection Approach","volume":"Volume 92","author":"Mittal","year":"2017","journal-title":"Mayo Clinic Proceedings"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jocn.2012.12.025","article-title":"Safety and efficacy of botulinum toxin in primary orthostatic tremor","volume":"20","author":"Bertram","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.0b013e31825dcdd9","article-title":"A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor","volume":"79","author":"Sung","year":"2012","journal-title":"Neurology"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archneur.61.9.1416","article-title":"Botulinum toxin type A for treating voice tremor","volume":"61","author":"Adler","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1212\/WNL.45.4.822","article-title":"Botulinum toxin treatment of essential head tremor","volume":"45","author":"Pahwa","year":"1995","journal-title":"Neurology"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Rajan, R., Srivastava, A.K., Anandapadmanabhan, R., Saini, A., Upadhyay, A., Gupta, A., Vishnu, V.Y., Pandit, A.K., Vibha, D., and Singh, M.B. (2020). Assessment of Botulinum Neurotoxin Injection for Dystonic Hand Tremor. JAMA Neurol.","DOI":"10.1001\/jamaneurol.2020.4766"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JPD-140379","article-title":"Sialorrhea in patients with Parkinson\u2019s disease: Safety and administration of botulinum neurotoxin","volume":"4","author":"Egevad","year":"2014","journal-title":"J. Parkinsons. Dis."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2018.12.002","article-title":"Use of botulinum toxin in Parkinson\u2019s disease","volume":"59","author":"Jocson","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.23522","article-title":"Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson\u2019s disease: Unfavorable risk-benefit ratio","volume":"26","author":"Espay","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.toxicon.2017.08.018","article-title":"Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections","volume":"147","author":"Cardoso","year":"2018","journal-title":"Toxicon"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","article-title":"Disease-oriented approach to botulinum toxin use","volume":"54","author":"Jankovic","year":"2009","journal-title":"Toxicon"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mds.21019","article-title":"Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson\u2019s disease","volume":"21","author":"Schneider","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_229","first-page":"282","article-title":"Botulinum toxin type B for gait freezing in Parkinson\u2019s disease","volume":"10","author":"Fernandez","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"ref_230","first-page":"147","article-title":"Botulinum toxin treatment of freezing of gait in Parkinson\u2019s disease patients as reflected in functional magnetic resonance imaging of leg movement","volume":"37","author":"Hok","year":"2016","journal-title":"Neuroendocrinol. Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2008.01612.x","article-title":"Botulinum toxin type A in the treatment of sialorrhea in Parkinson\u2019s disease","volume":"56","author":"Santamato","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.07.001","article-title":"Drooling in Parkinson\u2019s disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins","volume":"30","author":"Narayanaswami","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","article-title":"Botulinum Toxin A for Overactive Bladder and Detrusor Muscle Overactivity in Patients With Parkinson\u2019s Disease and Multiple System Atrophy","volume":"182","author":"Giannantoni","year":"2009","journal-title":"J. Urol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder","volume":"186","author":"Giannantoni","year":"2011","journal-title":"J. Urol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2005.02669.x","article-title":"Outlet type constipation in Parkinson\u2019s disease: Results of botulinum toxin treatment","volume":"22","author":"Cadeddu","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00702-019-01986-1","article-title":"Hand, foot, and spine deformities in parkinsonian disorders","volume":"126","author":"Wijemanne","year":"2019","journal-title":"J. Neural Transm."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.21967","article-title":"Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia","volume":"23","author":"Raible","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.parkreldis.2014.06.002","article-title":"Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle","volume":"20","author":"Wijemanne","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/mds.22676","article-title":"Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin","volume":"24","author":"Fietzek","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxicon.2015.06.004","article-title":"Treatment of camptocormia with botulinum toxin","volume":"107","author":"Bertram","year":"2015","journal-title":"Toxicon"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mds.870130330","article-title":"Extensor truncal dystonia: Successful treatment with botulinum toxin injections","volume":"13","author":"Comella","year":"1998","journal-title":"Mov. Disord."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clineuro.2008.12.007","article-title":"Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson\u2019s disease patients?","volume":"111","author":"Rodrigues","year":"2009","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00702-015-1416-2","article-title":"The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson\u2019s disease","volume":"123","author":"Jost","year":"2016","journal-title":"J. Neural Transm."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.10.009","article-title":"Incobotulinum toxin A in Parkinson\u2019s disease with foot dystonia: A double blind randomized trial","volume":"46","author":"Rieu","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/cjn.2017.245","article-title":"Botulinum Toxin Type A for Pain in Advanced Parkinson\u2019s Disease","volume":"45","author":"Bruno","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/mds.21694","article-title":"Botulinum toxin treatment of lateral axial dystonia in Parkinsonism","volume":"22","author":"Bonanni","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.parkreldis.2014.07.015","article-title":"Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study","volume":"20","author":"Tassorelli","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: A prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling","volume":"256","author":"Lagalla","year":"2009","journal-title":"J. Neurol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.parkreldis.2007.01.007","article-title":"Botulinum toxin A for drooling in Parkinson\u2019s disease: A pilot study to compare submandibular to parotid gland injections","volume":"13","author":"Kalf","year":"2007","journal-title":"Park. Relat. Disord."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/01.wnl.0000172930.63669.c8","article-title":"Botulinum toxin injections do not improve freezing of gait in Parkinson disease","volume":"65","author":"Wieler","year":"2005","journal-title":"Neurology"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clineuro.2003.10.012","article-title":"Ultrasound-guided versus \u201cblind\u201d intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson\u2019s disease","volume":"106","author":"Dogu","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0310057X1003800624","article-title":"Botulinum toxin to control an incapacitating tic in a child with a clavicular fracture","volume":"38","author":"Chen","year":"2010","journal-title":"Anaesth. Intensive Care"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/mds.870090315","article-title":"Botulinum toxin in the treatment of dystonic tics","volume":"9","author":"Jankovic","year":"1994","journal-title":"Mov. Disord."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","article-title":"Botulinum toxin in the treatment of tics","volume":"57","author":"Kwak","year":"2000","journal-title":"Arch. Neurol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.parkreldis.2009.11.011","article-title":"Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects","volume":"16","author":"Rath","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","article-title":"Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial","volume":"56","author":"Marras","year":"2001","journal-title":"Neurology"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","article-title":"Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A","volume":"24","author":"Porta","year":"2004","journal-title":"Neurol. Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/mds.21599","article-title":"Malignant Tourette syndrome","volume":"22","author":"Cheung","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870110413","article-title":"Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette\u2019s syndrome","volume":"11","author":"Scott","year":"1996","journal-title":"Mov. Disord."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/088307389901401203","article-title":"Treatment of childhood myoclonus with botulinum toxin type A","volume":"14","author":"Awaad","year":"1999","journal-title":"J. Child Neurol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mdc3.12986","article-title":"Myoclonus: An Electrophysiological Diagnosis","volume":"7","author":"Merchant","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/mds.20991","article-title":"Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis","volume":"21","author":"Browner","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_267","first-page":"672","article-title":"Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin","volume":"27","author":"Krause","year":"2006","journal-title":"Otol. Neurotol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/1531-8257(199901)14:1<182::AID-MDS1040>3.0.CO;2-8","article-title":"Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A","volume":"14","author":"Lagueny","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1468-1331.2012.03780.x","article-title":"Botulinum toxin is effective in myoclonus secondary to peripheral nerve injury","volume":"19","author":"Bono","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20516","article-title":"Palatal myoclonus: An unusual presentation","volume":"20","author":"Ross","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/lary.23485","article-title":"Palatal myoclonus: Algorithm for management with botulinum toxin based on clinical disease characteristics","volume":"124","author":"Sinclair","year":"2014","journal-title":"Laryngoscope"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.26093","article-title":"Myorhythmia: Phenomenology, etiology, and treatment","volume":"30","author":"Cardoso","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/practneurol-2017-001762","article-title":"Restless Legs Syndrome: Clinical features, diagnosis and a practical approach to management","volume":"17","author":"Wijemanne","year":"2017","journal-title":"Pract. Neurol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.52.5.1060","article-title":"Motor system excitability in patients with restless legs syndrome","volume":"52","author":"Tergau","year":"1999","journal-title":"Neurology"},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Mittal, S.O., Machado, D., Richardson, D., Dubey, D., and Jabbari, B. (2018). Botulinum toxin in restless legs syndrome\u2014A randomized double-blind placebo-controlled crossover study. Toxins, 10.","DOI":"10.3390\/toxins10100401"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.sleep.2012.08.019","article-title":"A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome","volume":"13","author":"Ghorayeb","year":"2012","journal-title":"Sleep Med."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.sleep.2008.03.002","article-title":"Failure of botulinum toxin A to relieve restless legs syndrome","volume":"10","author":"Ghorayeb","year":"2009","journal-title":"Sleep Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5664\/jcsm.26585","article-title":"Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A","volume":"2","author":"Rotenberg","year":"2006","journal-title":"J. Clin. Sleep Med."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/01.wnl.0000325994.93782.a1","article-title":"Double-blind, placebo-controlled, pilot trial of botulinum toxin a in restless legs syndrome","volume":"71","author":"Nahab","year":"2008","journal-title":"Neurology"},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Matak, I., B\u00f6lcskei, K., Bach-Rojecky, L., and Helyes, Z. (2019). Mechanisms of botulinum toxin type A action on pain. Toxins, 11.","DOI":"10.3390\/toxins11080459"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Mittal, S.O.M., and Jabbari, B. (2020). Botulinum neurotoxins and cancer\u2014A review of the literature. Toxins, 12.","DOI":"10.3390\/toxins12010032"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Weise, D., Weise, C.M., and Naumann, M. (2019). Central effects of botulinum neurotoxin\u2014evidence from human studies. Toxins, 11.","DOI":"10.3390\/toxins11010021"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1523\/JNEUROSCI.0294-18.2018","article-title":"Transynaptic action of botulinum neurotoxin type a at central cholinergic boutons","volume":"38","author":"Caleo","year":"2018","journal-title":"J. Neurosci."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Caleo, M., and Restani, L. (2018). Exploiting botulinum neurotoxins for the study of brain physiology and pathology. Toxins, 10.","DOI":"10.3390\/toxins10050175"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40478-018-0587-0","article-title":"Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment","volume":"6","author":"Okuzumi","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-Synuclein in Parkinson\u2019s Disease: Progress Towards the Development of Disease-Modifying Therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: Etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Rasetti-escargueil, C., and Popoff, M.R. (2021). Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins, 13.","DOI":"10.3390\/toxins13010001"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:08:37Z","timestamp":1760159317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":288,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["toxins13010042"],"URL":"https:\/\/doi.org\/10.3390\/toxins13010042","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}